Troubled Endo shelves cellulite treatment Qwo, lays off 90 employees

Just nine months after launching its “Butt First” campaign—designed to spark sales of its groundbreaking cellulite treatment—troubled Endo has pulled the plug on Qwo (collagenase clostridium histolyticum-aaes).

The Dublin, Ireland-based company said on Tuesday that it will cease production and sale of Qwo because of concerns about injection site bruising and skin discoloration.